Suppr超能文献

佩罗尼氏病的分子机制与当前药物治疗:综述

Molecular Mechanisms and Current Pharmacotherapy of Peyronie's Disease: A Review.

作者信息

Zhang Fuxun, Qin Feng, Yuan Jiuhong

机构信息

Andrology Laboratory, West China Hospital, Sichuan University, Chengdu, China.

Department of Urology, West China Hospital, Sichuan University, Chengdu, China.

出版信息

Front Pharmacol. 2021 May 20;12:643641. doi: 10.3389/fphar.2021.643641. eCollection 2021.

Abstract

Peyronie's disease (PD) is a localized fibrotic lesion of the penis that has adverse effects on men's health. In this review, we summarized the molecular mechanisms and pharmacotherapies of PD. A literature search was conducted using PubMed and Cochrane Library during 2001-2020. Although no oral or topical medication demonstrated efficacy in monotherapy of PD, several intralesional medications have yielded promising results. Currently, the effective strategy in management of PD should be combined modality therapy, including but not limited to pharmacotherapy, mechanical therapy, and psychotherapy. Meanwhile, basic research is still necessary to facilitate the development of novel and more reliable treatments. In future, more attention should be given simultaneously to epigenetic changes, inflammatory cytokines, the abnormal wound-healing process, and profibrotic and anti-fibrotic factors to provide more options for this refractory disease.

摘要

佩罗尼氏病(PD)是阴茎的一种局限性纤维化病变,对男性健康有不良影响。在本综述中,我们总结了佩罗尼氏病的分子机制和药物治疗方法。在2001年至2020年期间,使用PubMed和考科蓝图书馆进行了文献检索。尽管没有口服或局部用药在佩罗尼氏病的单一疗法中显示出疗效,但几种病灶内用药已取得了有希望的结果。目前,佩罗尼氏病管理的有效策略应是联合治疗,包括但不限于药物治疗、机械治疗和心理治疗。同时,基础研究对于促进新型且更可靠治疗方法的开发仍然是必要的。未来,应同时更加关注表观遗传变化、炎性细胞因子、异常的伤口愈合过程以及促纤维化和抗纤维化因子,以便为这种难治性疾病提供更多选择。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1b2/8173627/abfffecd922a/fphar-12-643641-g001.jpg

相似文献

1
Molecular Mechanisms and Current Pharmacotherapy of Peyronie's Disease: A Review.
Front Pharmacol. 2021 May 20;12:643641. doi: 10.3389/fphar.2021.643641. eCollection 2021.
2
Review of Management Options for Patients With Atypical Peyronie's Disease.
Sex Med Rev. 2017 Apr;5(2):211-221. doi: 10.1016/j.sxmr.2016.07.004. Epub 2016 Aug 17.
3
Review of Management Options for Active-Phase Peyronie's Disease.
Sex Med Rev. 2019 Apr;7(2):329-337. doi: 10.1016/j.sxmr.2018.09.007. Epub 2018 Nov 30.
4
Collagenase Clostridium histolyticum in the management of Peyronie's disease: a review of the evidence.
Ther Adv Urol. 2016 Jun;8(3):192-202. doi: 10.1177/1756287216637569. Epub 2016 Mar 22.
5
Peyronie's disease: What's around the bend?
Indian J Urol. 2016 Jan-Mar;32(1):6-14. doi: 10.4103/0970-1591.173107.
6
Pharmacological Management of Peyronie's Disease.
Drugs. 2007;67(4):527-45. doi: 10.2165/00003495-200767040-00004.
7
PEYRONIE'S DISEASE: A REVIEW OF ETIOLOGY, DIAGNOSIS, AND MANAGEMENT.
Curr Sex Health Rep. 2015 Jun 1;7(2):117-131. doi: 10.1007/s11930-015-0045-y.
8
Oral therapy for Peyronie's disease, does it work?
Transl Androl Urol. 2016 Jun;5(3):296-302. doi: 10.21037/tau.2016.03.24.
9
10

引用本文的文献

2
Injectable agents for the induction of Peyronie's disease in model rats: a comparative study.
Asian J Androl. 2025 Jan 1;27(1):96-100. doi: 10.4103/aja202430. Epub 2024 Aug 13.
6
Characterization of a novel rabbit model of Peyronie's disease.
Int J Impot Res. 2024 May;36(3):269-274. doi: 10.1038/s41443-023-00671-y. Epub 2023 Feb 13.
7
Peyronie's Disease: An Outcomes-Based Guide to Non-Surgical and Novel Treatment Modalities.
Res Rep Urol. 2023 Feb 2;15:55-67. doi: 10.2147/RRU.S278796. eCollection 2023.
8
Phenotypic screening of 1,953 FDA-approved drugs reveals 26 hits with potential for repurposing for Peyronie's disease.
PLoS One. 2022 Dec 12;17(12):e0277646. doi: 10.1371/journal.pone.0277646. eCollection 2022.

本文引用的文献

1
Peyronie Disease.
JAMA. 2020 Dec 22;324(24):2566. doi: 10.1001/jama.2020.14819.
2
New insights into the pathogenesis of Peyronie's disease: A narrative review.
Chronic Dis Transl Med. 2020 Jul 27;6(3):165-181. doi: 10.1016/j.cdtm.2020.06.001. eCollection 2020 Sep.
4
Evolving therapies for Peyronie's disease: how can we work towards new drugs?
Transl Androl Urol. 2020 Mar;9(Suppl 2):S284-S294. doi: 10.21037/tau.2019.08.09.
5
Peyronie's disease: is it genetic or not?
Transl Androl Urol. 2020 Mar;9(Suppl 2):S262-S268. doi: 10.21037/tau.2019.10.21.
7
Medical Management of Peyronie's Disease: Review of the Clinical Evidence.
Med Sci (Basel). 2019 Sep 18;7(9):96. doi: 10.3390/medsci7090096.
9
Pathophysiology and Future Therapeutic Perspectives for Resolving Fibrosis in Peyronie's Disease.
Sex Med Rev. 2019 Oct;7(4):679-689. doi: 10.1016/j.sxmr.2019.02.004. Epub 2019 Apr 5.
10
Collagenase Management of Multicord Dupuytren's Disease under Intravenous Sedation: A Prospective Cohort Study.
Plast Reconstr Surg Glob Open. 2019 Feb 20;7(2):e2133. doi: 10.1097/GOX.0000000000002133. eCollection 2019 Feb.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验